Cystic Fibrosis

Cystic fibrosis (CF) is an inherited, multisystem disease caused by disease-causing variants in the CFTR gene. Its autosomal recessive inheritance generally involves one affected copy inherited from each biological parent. The CFTR protein regulates salt and water transport across epithelial surfaces; impaired function produces abnormally thick secretions in several organs and unusually salty sweat. The lungs and digestive system are particularly affected, although the severity and combination of manifestations vary considerably. (nhlbi.nih.gov)

Persistent airway obstruction, infection, and inflammation can cause progressive lung damage, while pancreatic dysfunction can impair digestion and growth. Once predominantly associated with childhood mortality, cystic fibrosis increasingly extends through adulthood because of earlier detection, specialized care, and improved treatments. CFTR modulators address particular defects in the protein itself, but do not benefit every affected person and are not a cure. Understanding the disease therefore involves its molecular mechanisms, clinical manifestations, screening and diagnosis, treatment, and changing long-term outcomes. (nhlbi.nih.gov)

Inheritance and CFTR Variation

Cystic fibrosis (CF) follows autosomal recessive inheritance: disease results from CF-causing variants affecting both copies of the CFTR gene, located on chromosome 7q31.2. A person with one CF-causing variant and a normally functioning second copy is a carrier, generally without CF, but able to transmit the variant to offspring. The two disease-associated alleles need not contain the same change. An affected person may be homozygous, carrying the same variant on both copies, or compound heterozygous, carrying a different CF-causing variant on each copy. (pmc.ncbi.nlm.nih.gov)

When both biological parents carry one CF-causing variant, each pregnancy has a 25% probability of a child inheriting both variants and having CF, a 50% probability of a carrier child, and a 25% probability of a child inheriting neither familial variant. These probabilities apply independently to each pregnancy and do not imply that four children must comprise one affected child, two carriers, and one non-carrier. The inheritance probabilities are the same whether the parents carry identical or different CF-causing variants. (nhlbi.nih.gov)

The arrangement of variants—called their phase—is essential to interpreting a genotype. Two variants in trans lie on opposite gene copies, whereas two variants in cis lie on the same copy and may constitute a complex allele. Thus, detecting two sequence changes does not by itself demonstrate that both CFTR copies are affected: if both changes are in cis and the other copy functions normally, the finding does not establish the biallelic genetic basis of CF. Testing parents or other relatives can establish phase, particularly when a rare or previously uncharacterized variant accompanies a known pathogenic variant. The American College of Medical Genetics and Genomics addressed this distinction explicitly in its 2020 CFTR testing standard. (pmc.ncbi.nlm.nih.gov)

F508del, also written p.Phe508del or ΔF508, is the most common CF-causing variant. It deletes phenylalanine at position 508 of the CFTR protein. Its principal effect is defective protein folding and processing: cellular quality-control mechanisms recognize the abnormal protein and degrade much of it before it reaches the cell membrane. Even when F508del-CFTR reaches the surface, it can exhibit impaired channel opening and reduced stability there. F508del therefore illustrates why one variant may produce several molecular defects rather than fit exclusively into one functional category. (ncbi.nlm.nih.gov)

A commonly used six-class scheme distinguishes absent or severely impaired protein production, often caused by premature stop signals (class I); defective folding and intracellular trafficking (class II); defective gating, exemplified by G551D, in which surface channels open inadequately (class III); reduced ion conductance through the channel (class IV); reduced production of otherwise functional protein, including some splicing defects (class V); and accelerated loss or instability of surface protein (class VI). These categories describe mechanisms, not a uniform ranking of clinical severity, and overlapping defects can occur within a single variant. (cff.org)

Functional classification is distinct from evidence that a variant causes disease. A benign variant is not equivalent to a CF-causing variant, while a variant of uncertain significance lacks sufficient evidence for a confident pathogenic or benign classification. Finding two uncertain variants, or one established CF-causing variant and one uncertain variant, does not by itself establish CF. CFTR2 also recognizes variants of varying clinical consequence: when paired with a CF-causing allele, these may be associated with CF in some individuals but not others. Such findings require interpretation alongside clinical features and evidence of CFTR dysfunction, rather than counting every detected sequence difference as a disease-causing mutation. (pmc.ncbi.nlm.nih.gov)

Epithelial Transport and Disease Mechanisms

The cystic fibrosis transmembrane conductance regulator (CFTR) is an ion channel in the apical, or lumen-facing, cell membrane of epithelial cells. It conducts chloride and bicarbonate ions, helping control the volume and chemical composition of secretions. Ion movement through CFTR follows electrochemical gradients; the channel does not itself pump water. Instead, coordinated electrolyte transport creates osmotic forces that move water across epithelia. In airways and pancreatic ducts, CFTR-dependent anion secretion supports fluid secretion, while bicarbonate contributes to alkalinity. A 1992 study of cultured human airway epithelia demonstrated that cyclic AMP stimulated bicarbonate secretion in non-CF cells but not in CF cells. (jci.org)

Airway mucus normally traps inhaled particles and microorganisms, and beating cilia propel it toward the throat. This mucociliary clearance requires adequately hydrated mucus and an underlying fluid environment that permits effective ciliary movement. Reduced CFTR-dependent secretion increases mucus concentration and impairs its transport. The defect is therefore more specific than simply “producing too much mucus”: secreted mucins fail to acquire or maintain their normal hydrated organization. Experiments published in 2017 using human airway epithelial cultures found abnormal postsecretory unfolding of the mucin MUC5B, with surface dehydration identified as the major determinant under the conditions studied. (submit.jci.org)

Bicarbonate deficiency can also alter mucus properties and antimicrobial defenses, independently of a simple reduction in fluid volume. In 2012, Alejandro Pezzulo and colleagues studied newborn CF pigs before established infection and inflammation. Their airway surface liquid was more acidic and killed bacteria less effectively than that of non-CF pigs. Experimentally raising its pH improved bacterial killing, whereas lowering pH in non-CF airways impaired it. These findings identify an early host-defense defect in that animal model; they do not establish that every human CF airway has a persistently reduced pH. Experiments in CF rats subsequently showed that bicarbonate replacement could improve mucus transport in excised tracheae. (pmc.ncbi.nlm.nih.gov)

Retained secretions obstruct small airways and allow microorganisms to persist, provoking inflammation that further impairs clearance. The resulting cycle involves mucus retention, infection, inflammatory injury, and progressive structural damage, including bronchiectasis, the permanent dilation of damaged bronchi. Inflammation can also become difficult to resolve: a 2002 study found that CF airway fluid inhibited macrophage removal of dying inflammatory cells in vitro through a neutrophil-elastase-dependent mechanism. This provides one mechanism by which the inflammatory environment can perpetuate itself rather than merely reflect the presence of bacteria. (ncbi.nlm.nih.gov)

In the pancreas, ductal epithelial cells normally add bicarbonate-rich fluid to the enzyme-containing secretion produced by acinar cells. CFTR was localized to human pancreatic centroacinar and small duct cells in a 1991 study, linking its distribution to this secretory function. Impaired bicarbonate and fluid secretion leaves pancreatic juice insufficiently alkalinized and hydrated, favoring concentrated protein plugs and duct obstruction. Blockage prevents normal delivery of digestive enzymes to the intestine and contributes to progressive exocrine pancreatic injury; the resulting nutritional manifestations are downstream consequences of this transport defect. (jci.org)

Sweat ducts illustrate the opposite transport problem: defective salt reabsorption, rather than defective fluid secretion. As primary sweat passes through the duct, chloride normally enters epithelial cells through CFTR, alongside sodium absorption through epithelial sodium channels. The duct has relatively low water permeability, allowing salt removal without equivalent water removal. When chloride conductance is lost, the electrical gradient also limits further sodium absorption, leaving both ions in the sweat. Elevated sweat chloride therefore reflects failure to reclaim chloride from an already formed secretion—not the same mechanism that concentrates airway mucus. (jci.org)

Epidemiology and Population Variation

Birth incidence estimates depend on geography, birth cohort, and allowance for diagnoses made after infancy. A population-based study using Canadian and United States registry and vital-statistics data from 1995–2019 estimated that CF affected approximately 1 in 3,848 live births in Canada and about 1 in 5,100 in the United States in 2019, after adjustment for delayed diagnosis and the timing of screening implementation. Regional estimates ranged from 1 in 3,000 births in Canada’s Atlantic provinces to 1 in 6,925 in the Pacific United States. These estimates describe affected births, not the number of newly diagnosed patients in a calendar year, which includes people born in earlier years. (pmc.ncbi.nlm.nih.gov)

Prevalence measures people living with CF and therefore also reflects survival and population movement. Elizabeth Cromwell and colleagues’ study of the United States in 2020 estimated approximately 40,000 affected individuals. Within its modeled population born in the United States during 1968–2020, the estimated number alive was 38,804, with a 95% uncertainty interval of 38,532–39,065; older people and foreign-born residents were considered separately. Only 77% of that modeled birth-cohort population contributed registry data in 2019 or 2020. Registry enrollment was higher among children than older adults, illustrating why a registry count should not automatically be treated as complete national prevalence. (cysticfibrosisjournal.com)

Carrier-frequency estimates likewise require a defined population and testing method. Val Zvereff and colleagues analyzed North American laboratory referrals collected from January 2005 through December 2010. Among 109,830 individuals tested with a 69-variant panel, the observed carrier frequency was 1 in 36 overall, including 1 in 27 among participants classified as Caucasian, 1 in 79 among African-American participants, and 1 in 48 among Hispanic-American participants. The Hispanic-American frequency observed with a smaller, 32-variant panel was 1 in 69. These were clinical referral samples rather than random population surveys, and the contrast shows how panel composition affects measured carrier frequency as well as reflecting underlying allele distributions. (nature.com)

Ancestry-associated differences concern variant distributions, not a restriction of CF to one ancestry. In Meghan McGarry and colleagues’ analysis of 46,729 genotyped people with CF recorded in the US registry through 2020, at least one F508del copy was present in 87.5% of non-Hispanic White patients, 66.1% of Hispanic patients, 53.7% of non-Hispanic Black patients, and 41.9% of non-Hispanic Asian patients. These are proportions among diagnosed patients, not carrier frequencies in the general population. Broad racial and ethnic classifications also encompass substantial ancestral diversity. (onlinelibrary.wiley.com)

Newborn screening changes case ascertainment by identifying affected infants before symptom-based diagnosis. Nevertheless, algorithms requiring a detected CFTR variant can miss infants whose variants are absent from the panel. Using the same registry dataset, the conventional 23-variant panel would identify at least one variant in 95.3% of non-Hispanic White patients, compared with 81.0% of Hispanic, 73.4% of non-Hispanic Black, and 56.2% of non-Hispanic Asian patients. These modeled genetic detection rates are not the sensitivity of an entire screening program, which also depends on biochemical thresholds and diagnostic follow-up. (onlinelibrary.wiley.com)

Comparisons between populations must therefore account for screening coverage, access to confirmatory testing and specialist services, and registry inclusion rules. The Canadian–US incidence study excluded CFTR-related disorders and inconclusive screening diagnoses, and adjusted for patients expected to receive a later diagnosis. Without those adjustments, observed 2019 birth-cohort counts underestimated incidence by approximately 12% in Canada and 10% in the United States. A recent birth cohort can consequently appear to have unusually low incidence simply because some affected individuals have not yet been diagnosed or entered into surveillance systems. (pmc.ncbi.nlm.nih.gov)

Respiratory Manifestations and Airway Infection

Persistent productive cough, thick sputum, wheeze, and recurrent respiratory infections are characteristic respiratory manifestations, although their severity varies considerably. Upper-airway involvement includes chronic rhinosinusitis and nasal polyps, which can obstruct nasal airflow. In the lower airways, retained secretions, infection, and inflammation contribute to bronchiectasis—permanent abnormal widening of the bronchi. Dilated, damaged airways clear secretions poorly, sustaining further infection and injury. Structural disease can begin early: bronchiectasis has been detected in infants with CF as young as ten weeks. (nhlbi.nih.gov)

Pulmonary exacerbations are episodes of respiratory deterioration superimposed on the underlying lung disease. Features include increased cough, greater sputum production or altered sputum color, worsening wheeze or breathlessness, and declining lung function. Fever, fatigue, reduced appetite, and weight loss may accompany the respiratory changes. These episodes reflect worsening airway infection and inflammation rather than necessarily the acquisition of a new organism. Repeated exacerbations are associated with subsequent loss of lung function and poorer quality of life. (nhlbi.nih.gov)

Characteristic airway bacteria include Staphylococcus aureus, including methicillin-resistant strains, and Pseudomonas aeruginosa. Their distribution varies with age: the Cystic Fibrosis Foundation’s August 2020 infection-research white-paper addendum described S. aureus as more common in children and P. aeruginosa as more common in adults. Once established, P. aeruginosa can be difficult to eliminate; mucus supports bacterial communities within protective biofilms that make organisms harder to kill. The Burkholderia cepacia complex comprises several related species, including B. cenocepacia and B. multivorans, and commonly exhibits resistance to multiple antibiotics. Its clinical effects range from persistent infection without obvious acceleration of disease to rapid, sometimes fatal respiratory deterioration. Environmental acquisition and transmission between people with CF are both documented for Pseudomonas and Burkholderia. (cff.org)

Nontuberculous mycobacteria, particularly Mycobacterium avium complex and M. abscessus complex, introduce an important distinction between organism detection and active disease. They may remain in the airways without causing progressive damage, whereas nontuberculous mycobacterial pulmonary disease requires a combination of clinical, radiological, and microbiological evidence. The joint US Cystic Fibrosis Foundation–European Cystic Fibrosis Society consensus recommendations published in January 2016 explicitly recognized this distinction. Among fungi, Aspergillus fumigatus can provoke allergic bronchopulmonary aspergillosis (ABPA), an immune hypersensitivity disorder rather than simply a positive fungal culture. ABPA may produce wheeze, mucus plugging, new pulmonary opacities, and declining lung function; its overlap with ordinary CF exacerbations can complicate recognition. (cff.org)

Advanced airway disease can cause hemoptysis, ranging from blood-streaked sputum to major bleeding when damaged blood vessels bleed into the airways. Pneumothorax occurs when air enters the space between the lung and chest wall, allowing partial or complete lung collapse and typically producing sudden chest pain or breathlessness. Progressive destruction and obstruction of the lungs can eventually impair gas exchange sufficiently to cause respiratory failure. Despite improvements in treatment and survival, advanced CF lung disease remains the most common cause of death; chronic infection and inflammation are central contributors to this progression. (nhlbi.nih.gov)

Digestive, Metabolic, and Reproductive Manifestations

Exocrine pancreatic insufficiency develops when poorly hydrated secretions obstruct ducts in the pancreas, with progressive injury reducing the delivery of digestive enzymes to the intestine. Inadequate fat digestion produces steatorrhea—bulky, greasy stools—and contributes to abdominal distension, poor weight gain, and impaired childhood growth. Malabsorption also causes deficiencies of the fat-soluble vitamins A, D, E, and K, affecting vision, skeletal mineralization, neurological function, and blood clotting, respectively. Pancreatic sufficiency means that enough exocrine function remains for digestion; it does not imply a normal pancreas. People with preserved enzyme production can develop acute or recurrent pancreatitis, because functioning secretory tissue remains vulnerable to duct obstruction and inflammation. (ncbi.nlm.nih.gov)

Meconium ileus is a neonatal obstruction caused by unusually thick first intestinal contents, usually in the distal small bowel. It can produce failure to pass meconium, abdominal distension, and bilious vomiting. The United Kingdom’s 2017 NICE guideline, drawing on UK CF Registry data, described it in approximately one in seven newborns with CF. By contrast, distal intestinal obstruction syndrome (DIOS) occurs after the neonatal period, when dehydrated intestinal material obstructs the terminal ileum and adjacent colon. DIOS may be incomplete or complete and typically causes relatively acute abdominal pain and distension. Constipation is distinct: stool accumulates more gradually throughout the colon rather than forming a localized ileocecal obstruction. Hepatobiliary involvement includes abnormal liver enzymes, impaired bile flow, gallbladder disease, and fibrosis; advanced disease may involve cirrhosis and portal hypertension. These manifestations vary substantially between individuals. (ncbi.nlm.nih.gov)

CF-related diabetes (CFRD) is an endocrine complication, separate from the loss of digestive enzymes. Its principal defect is inadequate insulin secretion associated with pancreatic injury and impaired islet function; insulin resistance may additionally increase during infection, glucocorticoid exposure, or pregnancy. It is therefore neither conventional autoimmune type 1 diabetes nor simply type 2 diabetes. Hyperglycemia can initially occur without conspicuous thirst or excessive urination, while insulin deficiency contributes to loss of weight and muscle. The 2022 ISPAD consensus guideline reported that, in the 2020 US CF Foundation Registry, CFRD affected approximately 20% of people aged 20, 30% aged 30, and just under 40% aged 40. These are age-specific registry observations, not a uniform risk for everyone with CF. (cff.org)

Reduced bone mineral density and osteoporosis arise through several interacting mechanisms: malabsorption of vitamin D, inadequate nutrition, chronic inflammation, reduced weight-bearing activity, delayed puberty or hypogonadism, and glucocorticoid exposure. The resulting skeletal fragility increases fracture risk. Salt-loss dehydration has a different origin: defective salt reabsorption in sweat ducts produces excessive sodium and chloride losses, particularly during heavy sweating. This can cause volume depletion and electrolyte disturbances even without diarrhea or vomiting; it is not simply another consequence of intestinal malabsorption. (cff.org)

Male infertility usually results from congenital bilateral absence or severe underdevelopment of the vas deferens, preventing sperm from entering the ejaculate rather than necessarily preventing sperm production. Biological fatherhood can therefore be possible through sperm retrieval and assisted reproduction. Female fertility is variable rather than universally absent; altered reproductive-tract secretions, nutritional status, and systemic illness can reduce the likelihood of conception. Pregnancy is an established part of the adult disease spectrum, but maternal respiratory impairment and nutritional or metabolic complications influence outcomes. Premature delivery and low birth weight are recognized risks, particularly with reduced maternal lung function; pregnancy can also increase insulin requirements or reveal previously unrecognized glucose intolerance. (ncbi.nlm.nih.gov)

Screening, Diagnostic Confirmation, and Related Conditions

Newborn screening for cystic fibrosis begins with measurement of immunoreactive trypsinogen (IRT), a pancreatic biomarker, in dried blood collected by heel prick during the first days of life. Elevated IRT identifies infants requiring further testing; it does not establish CF, because concentrations can also rise after a stressful delivery or premature birth. Screening algorithms vary by jurisdiction and may combine IRT with testing for selected CFTR variants. DNA follow-up increases specificity but can identify carriers and miss disease-causing variants absent from the panel. A positive screen therefore initiates diagnostic assessment rather than constituting a confirmed diagnosis. (nhlbi.nih.gov)

The principal confirmatory investigation is the sweat chloride test. Pilocarpine, delivered through the skin using a small electrical current, stimulates sweating; collected sweat is then analyzed for chloride concentration. An inadequate sample requires recollection, not interpretation as a negative result. The Cystic Fibrosis Foundation’s 2017 diagnostic consensus specifies that, in someone with a positive newborn screen, compatible clinical findings, or a family history, a concentration of at least 60 mmol/L supports CF diagnosis. Values of 30–59 mmol/L are intermediate and require repeat testing and further investigation; below 30 mmol/L, CF is less likely but remains possible with certain variants and convincing clinical evidence. (cff.org)

Molecular testing distinguishes established CF-causing variants from variants of varying clinical consequence and findings whose significance remains uncertain. Two detected variants are not automatically diagnostic: their disease association and location on opposite copies of CFTR matter. Parental testing can establish whether variants occur together on one copy or separately on the two copies. In unresolved screen-positive cases, investigation can extend beyond a limited panel to DNA sequencing and deletion/duplication analysis. Failure to identify two CF-causing variants does not exclude CF, and an uncertain variant is not equivalent to a pathogenic finding. (cff.org) Specialized functional investigations include nasal potential difference, which measures voltage changes reflecting epithelial ion transport, and intestinal current measurement, which assesses transport responses in rectal biopsy tissue. These tests can clarify inconclusive sweat and genetic results in experienced reference centers. (pmc.ncbi.nlm.nih.gov)

A CFTR-related disorder is a clinical condition associated with CFTR dysfunction that does not satisfy diagnostic criteria for CF; examples include congenital bilateral absence of the vas deferens, pancreatitis, and bronchiectasis. This differs from CRMS/CFSPID—CFTR-related metabolic syndrome/cystic fibrosis screen-positive, inconclusive diagnosis—which describes an unresolved result after newborn screening in an infant without clinical features establishing CF. (cff.org) CRMS/CFSPID encompasses either sweat chloride below 30 mmol/L with two CFTR variants, at least one having unclear consequences, or sweat chloride of 30–59 mmol/L with one or no identified CF-causing variants. It is not a confirmed CF diagnosis. The Foundation’s 2024 guideline specifies repeat sweat testing at six months and annually through at least eight years, with reassessment incorporating clinical findings and evolving variant interpretation. (pmc.ncbi.nlm.nih.gov)

Carrier screening and prenatal diagnosis answer different questions from newborn screening. Carrier testing examines blood, saliva, or cheek-cell DNA for variants relevant to reproductive risk. A negative limited-panel result reduces but does not eliminate carrier probability, because untested variants remain possible; interpretation depends on test coverage and family history. When familial disease-causing variants are known, prenatal diagnostic testing can determine whether a fetus inherited them using DNA from chorionic villus sampling or amniocentesis. These procedures test fetal inheritance during pregnancy, whereas parental carrier screening estimates reproductive risk and newborn screening identifies infants needing postnatal confirmation. (acog.org)

Respiratory Treatment and Nutritional Support

Airway-clearance techniques mechanically mobilize retained secretions so that coughing can remove them. Chest physiotherapy combines percussion, vibration, and positioning; other approaches include controlled breathing with forced expiration (“huffing”), positive expiratory pressure devices, and high-frequency chest-wall oscillation vests. Positive expiratory pressure helps maintain airway opening during expiration, whereas oscillating devices add vibrations that loosen secretions. The 2009 Cystic Fibrosis Foundation pulmonary guidelines found no single technique consistently superior and emphasized selection according to age, preference, and clinical circumstances. Aerobic exercise supports fitness and secretion clearance but was classified as an adjunct rather than a replacement for airway-clearance therapy. (com-peds-pulmonary.sites.medinfo.ufl.edu)

Inhaled hypertonic saline and dornase alfa alter sputum through different mechanisms. Hypertonic saline, including 7% sodium chloride preparations, draws water into the airway lumen by an osmotic effect, improving mucus hydration and facilitating clearance. Dornase alfa is recombinant human deoxyribonuclease: it cleaves extracellular DNA released by inflammatory cells, which contributes to the viscosity of CF sputum. Thus, saline changes airway hydration, whereas dornase changes a molecular component of purulent secretions; neither mechanically evacuates mucus. Both are delivered by nebulizer and used alongside airway-clearance techniques. Bronchodilators may be included to open narrowed airways and reduce bronchospasm associated with inhaled treatments. (cff.org)

Antibiotic treatment distinguishes suppression of persistent infection from treatment of pulmonary exacerbations. Respiratory cultures identify organisms and inform antimicrobial selection; repeated assessment is important because airway microbiology and antibiotic susceptibility can change. Oral antibiotics can treat selected infections, while intravenous treatment is commonly used for more substantial exacerbations or when suitable oral options are unavailable. Inhaled tobramycin and aztreonam deliver antibiotics directly to the airways and are examples of treatments used against Pseudomonas aeruginosa. Chronic suppressive treatment aims to reduce bacterial activity and respiratory morbidity rather than necessarily eliminate established infection. Resistant organisms can progressively restrict therapeutic choices, making microbiological findings and clinical response important to ongoing treatment decisions. (cff.org)

For pancreatic exocrine insufficiency, pancreatic enzyme replacement supplies lipase, protease, and amylase to support digestion of fats, proteins, and starches. Preparations are taken with meals and relevant snacks so that enzymes reach the intestine with food. Treatment is assessed through growth or weight trajectory, stool characteristics, abdominal symptoms, and nutritional status. Enzyme quantities are expressed principally in lipase units; excessive dosing has been associated with fibrosing colonopathy, so persistent malabsorption is not automatically managed by increasing enzymes. Replacement improves nutrient availability but does not restore pancreatic secretion or completely normalize absorption. (cff.org)

Nutritional support ranges from individualized food plans and oral supplements to enteral tube feeding when oral intake cannot meet requirements. Supplementation commonly includes the fat-soluble vitamins A, D, E, and K, whose absorption is impaired by fat malabsorption. Although energy-dense diets remain important for undernutrition, the Foundation’s 2023 nutrition position paper recognized increasing overweight and obesity, particularly in the modulator era, and emphasized individualized energy intake and diet quality. CF-related diabetes is treated with insulin alongside nutritional management. Gastrointestinal treatment may include polyethylene glycol for constipation, acid-suppressing medication for reflux, and specialized medical or surgical management of intestinal obstruction. (cff.org)

Advanced respiratory disease may require supplemental oxygen for hypoxemia and noninvasive ventilation for inadequate ventilation with carbon dioxide retention. The Foundation’s 2020 advanced-lung-disease guidelines distinguish oxygen supplementation from nocturnal ventilatory support for chronic hypercarbia; acute respiratory failure may require invasive mechanical ventilation. Lung transplantation replaces severely damaged lungs and can improve survival and functioning in selected patients, but introduces risks of rejection, infection, and long-term immunosuppressive treatment. Donor lungs are not affected by the recipient’s CFTR defect, yet transplantation does not correct CF in the pancreas, intestines, liver, or other organs; those manifestations continue to require treatment. (cff.org)

CFTR Modulators and Genotype-Directed Treatment

CFTR modulators act on the defective CFTR protein rather than simply treating mucus accumulation or infection. Potentiators, exemplified by ivacaftor, increase the opening probability of CFTR ion channels already present at the cell membrane. Correctors, including tezacaftor and elexacaftor, improve protein folding and trafficking, increasing the amount of functional protein reaching the cell surface. These mechanisms are complementary: F508del-CFTR has both processing defects and impaired channel activity, so increasing its surface abundance alone does not fully restore chloride transport. Modulators improve protein function without replacing or editing the CFTR gene. (cff.org)

Ivacaftor illustrates how a specific molecular defect can determine treatment response. With the G551D gating variant, CFTR reaches the cell surface but opens infrequently; potentiation can therefore restore substantial channel activity. In a 2011 placebo-controlled randomized controlled trial, participants receiving ivacaftor had a treatment difference of 10.6 percentage points in percent-predicted forced expiratory volume in one second ($\mathrm{FEV}_1$) through week 24 and were 55% less likely to experience a pulmonary exacerbation through week 48. The United States Food and Drug Administration initially approved ivacaftor on January 31, 2012, for people aged six years or older with at least one G551D variant. That initial indication was subsequently expanded; it is not a description of present-day eligibility. (nejm.org)

Elexacaftor–tezacaftor–ivacaftor combines two correctors with a potentiator, addressing different defects in F508del-CFTR. In the pivotal 2019 trial involving people aged at least 12 years with one F508del allele and a second minimal-function allele, the combination increased percent-predicted $\mathrm{FEV}_1$ by 14.3 percentage points relative to placebo through 24 weeks. Pulmonary exacerbation rates were 63% lower, sweat chloride concentrations were 41.8 mmol/L lower, and respiratory quality-of-life scores improved. Benefit in this population demonstrated that rescuing protein produced from one responsive allele could be clinically effective even when the other contributed little or no functional CFTR. These results describe a defined trial population, not a uniform response across all genotypes. (nejm.org)

Variant responsiveness matters because a disease-causing variant does not necessarily produce a protein that a particular drug can rescue. Evidence supporting treatment selection can include clinical outcomes and laboratory measurements of drug-induced chloride transport. For example, the August 2023 United States prescribing information for elexacaftor–tezacaftor–ivacaftor included people aged two years or older with at least one F508del variant or a variant responsive in laboratory assays. This dated indication illustrates how genotype-directed eligibility is defined through product-specific regulatory evidence rather than the diagnosis alone. (accessdata.fda.gov)

Adverse effects of elexacaftor–tezacaftor–ivacaftor include headache, abdominal pain, diarrhea, rash, and elevated liver enzymes. Its 2025 United States labeling carries a boxed warning for potentially fatal drug-induced liver injury and liver failure, with liver testing before treatment, monthly during the first six months, every three months during the following 12 months, and at least annually thereafter. Pediatric safety surveillance includes baseline and follow-up eye examinations because lens opacities have been reported with ivacaftor-containing regimens. Drug interactions reflect pharmacokinetic effects: strong CYP3A inducers such as rifampin reduce exposure, whereas moderate or strong CYP3A inhibitors increase exposure and require prescribing adjustments. (accessdata.fda.gov)

Modulators cannot rescue protein that is not produced: when neither allele supplies a suitable CFTR substrate, these drugs lack their molecular target. Intolerance can also prevent sustained treatment, while insurance restrictions and financial barriers can interrupt access despite biological responsiveness. Their effects depend on continued administration, and improved CFTR function does not eradicate every disease manifestation. Persistent airway bacteria can remain difficult to clear even in responders; infection treatment, nutritional support, and organ-specific follow-up therefore remain distinct components of care. (cff.org)

Lifelong Care, Participation, and Access

Specialist CF centers coordinate care across organs and stages of life. Their multidisciplinary teams include physicians, nurses, dietitians, respiratory therapists, pharmacists, social workers, and mental health professionals, with endocrinology, gastroenterology, liver, reproductive-health, and transplant services involved as needed. Coordination connects otherwise separate decisions: dietitians and endocrinologists jointly address CF-related diabetes, while pharmacists check interactions among medicines prescribed by different specialists. Nurses often provide the main contact between visits, communicate changes in treatment, and identify psychological or financial difficulties. The person with CF and, where appropriate, family caregivers participate in setting goals and adapting care to daily circumstances. (cff.org)

Transition from pediatric to adult services is a planned transfer of both clinical care and responsibility, rather than a single referral. The US Cystic Fibrosis Foundation describes transfer as commonly occurring between ages 17 and 21. Preparation includes progressively assuming responsibility for treatments and equipment, communicating directly with clinicians, and understanding insurance arrangements. Adult teams also address education, employment, relationships, and parenthood; family involvement continues according to the adult patient’s preferences and consent. Social workers help arrange educational accommodations, navigate career decisions, and resolve coverage problems, linking participation outside healthcare with continuity of specialist care. (cff.org)

Daily management combines airway-clearance sessions, inhaled medicines, nutritional treatment, equipment cleaning, and appointments. These tasks can compete with school, work, and relationships, making treatment burden an important component of quality of life. (cff.org) Psychological care is therefore integrated into CF services rather than confined to responses to advanced disease. Joint Cystic Fibrosis Foundation–European Cystic Fibrosis Society consensus statements, first published online in October 2015, recommend annual depression and anxiety screening from age 12 using the PHQ-9 and GAD-7, and annual screening of at least one primary caregiver of children and adolescents. Elevated scores prompt clinical assessment rather than constituting a diagnosis; the guidance also specifies referral and treatment pathways. (cff.org)

Infection prevention shapes both clinic organization and contact between people with CF, because respiratory pathogens can pass between individuals. The Foundation’s 2013 guideline update, published in 2014, specifies hand hygiene, staff gowns and gloves during patient care, patient surgical masks in healthcare settings, and cleaning of shared equipment and surfaces. It recommends separation of at least six feet—approximately two meters—between people with CF regardless of culture results, with an exception for members of the same household. Clinics reduce shared waiting time through staggered appointments or direct placement in examination rooms, while hospitals use single-patient rooms. These arrangements also constrain in-person peer contact; the guideline explicitly recognizes their potential psychosocial effects. (cff.org)

Socioeconomic circumstances are associated with measurable differences in outcomes. A 2013 study by David Taylor-Robinson and colleagues examined 8,055 UK registry participants younger than 40 using observations from 1996–2009. Compared with children in the least deprived areas, those in the most deprived areas had lower growth measurements, a 4.12-percentage-point lower percent-predicted forced expiratory volume in one second, and higher odds of chronic Pseudomonas aeruginosa infection (odds ratio 1.89; 95% confidence interval 1.34–2.66). Disadvantaged participants were also less likely to receive DNase or inhaled antibiotics. These observational associations do not identify a single causal pathway, but document inequalities despite healthcare free at the point of use. (pubmed.ncbi.nlm.nih.gov)

Access to medicines also depends on financing by the health system, not simply biological eligibility. Jonathan Guo and colleagues’ 2025 study surveyed clinicians during February–November 2024 in 15 countries without CFTR-modulator reimbursement agreements. Alternative access routes were identified in 11 countries, including litigation, generic formulations, and donations. Apart from domestically produced generics in Argentina and an originator donation program in Ukraine, these routes reached only limited proportions of local CF populations because of substantial costs. The findings distinguish formal drug availability from sustained, affordable access to treatment. (spiral.imperial.ac.uk)

Disease Monitoring, Prognosis, and Survival

Serial spirometry tracks airflow limitation and response to treatment. A principal measure is forced expiratory volume in one second ($\mathrm{FEV}_1$), commonly expressed as a percentage of the predicted value for a person’s age, height, and sex. The 2025 United States Cystic Fibrosis Foundation registry highlights reported that median percent-predicted $\mathrm{FEV}_1$ was largely unchanged among 10- and 18-year-olds between 2021 and 2025, but increased among 30-year-olds. Lung function is one component of monitoring rather than a complete account of disease: respiratory cultures identify airway pathogens, while imaging assesses structural abnormalities such as bronchiectasis. GeneReviews describes pulmonary function testing frequently after age five, cultures at least every three months, and consideration of chest computed tomography every two years or when clinically indicated. (cff.org)

Surveillance also follows nutritional and extrapulmonary disease. Weight, height, and age-appropriate growth indices are assessed at each visit, including weight-for-length below age two and body mass index thereafter. Annual assessments include fat-soluble vitamin status, liver blood tests, and renal function and electrolytes. A two-hour oral glucose tolerance test is used annually from age ten to detect CF-related diabetes, while bone-density assessment is guided by age and risk factors for osteoporosis. Liver ultrasound, screening for depression and anxiety, and age-specific colorectal cancer screening address complications that may develop independently of changes in respiratory symptoms. (ncbi.nlm.nih.gov)

Dated registry observations document both longer survival and an older patient population. The US registry included 33,989 people in 2024; adults constituted 61.6%, compared with 33.8% in 1994, and 9.0% were aged 50 or older. Its 2024 report described reduced hospitalization rates and pulmonary exacerbations well below earlier levels. It recorded 61 lung transplants in 2024, substantially below pre-2020 volumes. Median predicted survival for the 2020–2024 observation period was 65.4 years, with a 95% confidence interval of 63.6–68.1 years; the 2025 highlights subsequently reported a rounded estimate of 66 years for 2021–2025. These are population observations during a period of major changes in treatment, not randomized estimates of the contribution of any single therapy. (cff.org)

Median predicted survival estimates the age beyond which half of a hypothetical population would survive if the mortality conditions represented by the observation period continued. It is not the observed lifespan of babies born during those years, nor does it incorporate unknown future improvements in treatment. By contrast, median age at death describes only those who died within a specified period: among deaths reported to the US registry in 2024, it was 38.8 years. This lower figure excludes people still alive and therefore does not contradict the higher predicted survival estimate. Conditional survival estimates additionally account for having already reached a particular age. Neither statistic specifies an individual’s remaining lifespan, which varies with disease severity, genotype, complications, and treatment response. (cff.org)

Registry coverage defines the limits of these estimates. The US Foundation registry collects information from consenting people attending Foundation-accredited centers; it is not a census of everyone with CF worldwide. Eligibility criteria also differ between analyses: the 2024 report included lung-transplant recipients in survival statistics but excluded them from most other clinical outcome chapters. Confidence intervals quantify statistical uncertainty, while incomplete ascertainment and differences in the populations included affect comparisons between reports. Because CF is uncommon, relatively small changes in recorded deaths can noticeably shift survival estimates; short-term fluctuations therefore require interpretation alongside longer trends. (cff.org)

Historical Recognition and Therapeutic Development

In 1938, Dorothy Hansine Andersen published a clinical and pathological study establishing cystic fibrosis as a distinct disease rather than a form of coeliac disease, with which its malnutrition and digestive symptoms had been confused. Working at Babies Hospital in New York, she connected characteristic abnormalities of the pancreas with intestinal and respiratory disease. The historical name “cystic fibrosis of the pancreas” referred to cystic enlargement of pancreatic ducts and replacement of damaged glandular tissue by fibrous scar tissue. It described the striking anatomical findings available to pathologists before the underlying molecular defect was known, rather than defining the condition as exclusively pancreatic. (jamanetwork.com)

Organized care and systematic observation developed alongside laboratory research. Parents founded the US Cystic Fibrosis Foundation in 1955; in 1961, it established an accredited care-center network with two centers devoted to the disease. The network provided an institutional basis for coordinated respiratory, nutritional, and other specialist services. In 1966, the Foundation launched its patient registry, initially collecting a limited set of demographic and survival information. Its subsequent expansion into a longitudinal clinical database allowed researchers to relate treatments and care practices to outcomes, examine differences between centers, and support quality-improvement programs. The Therapeutics Development Network, established in 1998, added an organized network of specialist research centers for multicenter clinical trials. These initiatives made repeated observations across patients and institutions part of both care delivery and therapeutic development. (cff.org)

The identification of CFTR in 1989 shifted research from describing organ damage to investigating its molecular cause. Researchers at Toronto’s Hospital for Sick Children, including Lap-Chee Tsui, John Riordan, and Johanna Rommens, collaborated with Francis Collins and colleagues at the University of Michigan. Three coordinated papers appeared in Science on September 8, 1989, reporting gene identification, complementary DNA characterization, and genetic analysis. The work identified the common F508del variant and established the sequence of the protein subsequently characterized as an epithelial ion channel. Identifying the gene made direct mutation testing possible and supplied the molecular target for investigating how different variants impair protein production, processing, or function. (sickkids.ca)

Important treatments initially addressed downstream consequences rather than CFTR itself. In 1993, the US Food and Drug Administration (FDA) approved dornase alfa, a recombinant human enzyme that breaks down extracellular DNA contributing to the viscosity of airway secretions. A 24-week randomized trial published in 1994 enrolled 968 children and adults; once-daily treatment reduced the age-adjusted risk of respiratory exacerbations by 28% relative to placebo. In 1997, the FDA approved inhaled tobramycin formulated for CF airway infection. The pivotal studies, published in 1999, enrolled 520 participants at 69 US centers and demonstrated improved pulmonary function, reduced sputum Pseudomonas aeruginosa density, and reduced hospitalization risk. These developments illustrate how multicenter trials converted mucus-directed and antimicrobial strategies into standardized therapies. (cff.org)

Protein-targeted treatment followed more than two decades after gene discovery. On January 31, 2012, the FDA initially approved ivacaftor for patients aged six years or older carrying G551D. As a potentiator, it improves opening of CFTR channels already present at the cell surface. Lumacaftor–ivacaftor received US approval in 2015, extending the approach to correction of defective protein folding and trafficking. On October 21, 2019, the FDA approved elexacaftor–tezacaftor–ivacaftor initially for patients aged at least 12 years with at least one F508del variant. Combining two correctors with a potentiator addressed multiple defects in the same protein, marking a transition from treating mucus obstruction and infection alone to modifying CFTR function itself. (fda.gov)

Genetic Therapies and Remaining Research Challenges

Investigational genetic treatments differ in what they deliver and how long their effects might last. Gene addition, a form of gene therapy, supplies functional CFTR DNA without necessarily correcting the existing variants. Non-integrating DNA remains separate from the chromosomes and may require repeated administration; integrating approaches insert DNA into the cellular genome, potentially sustaining expression but introducing risks associated with the insertion site. Messenger RNA delivery instead supplies instructions that cells translate directly into CFTR protein. It does not require nuclear entry or alter genomic DNA, but expression declines as the RNA and protein are degraded. Genome editing changes DNA sequences, potentially producing permanent correction within treated cells. Lasting benefit throughout an airway nevertheless depends on which cells are corrected and whether their descendants retain the change. Gene addition and CFTR mRNA replacement are intended to bypass many different disease-causing variants, whereas some editing strategies target particular variants. These remain investigational approaches for CF. (cff.org)

Delivery is a central obstacle. Inhaled genetic material must penetrate thick airway mucus, avoid clearance, enter epithelial cells, and escape intracellular membrane compartments; DNA-based approaches must additionally reach the nucleus. Viral vectors and non-viral carriers, including lipid particles, are being developed to overcome these barriers. Correcting accessible surface cells could restore transport temporarily, whereas durable correction may require reaching basal stem cells that replenish the airway lining. Such cells are harder to access from the airway surface. Moreover, inhaled treatment acts principally where its cargo is delivered: improvement in lung cells would not itself demonstrate correction in the pancreas, liver, or other affected organs. (cff.org)

Laboratory correction and clinical benefit are distinct milestones. In a 2024 study, researchers used prime editing to correct F508del in patient-derived airway epithelial cells, achieving a mean correction rate of approximately 25% and restoring CFTR channel activity to more than 50% of that measured in non-CF cells. These were cultured-cell results, not evidence of successful treatment in patients. Conversely, the 2023 report of the RESTORE-CF phase 1/2 randomized controlled trial illustrated the difficulties of translating RNA delivery into benefit: 42 adults received inhaled MRT5005, a lipid-particle formulation of CFTR mRNA, or placebo. No consistent improvement in lung function was observed, and febrile and hypersensitivity reactions occurred in some treated participants. (nature.com)

Trial design must distinguish successful delivery, restored CFTR function, and meaningful improvement in health. The Cystic Fibrosis Foundation’s November 2022 genetic-therapy guidance emphasized different evaluation requirements for repeatedly dosed transient therapies and potentially durable interventions. Early studies examine dose-related toxicity, airway inflammation, immune responses, and whether repeat administration remains feasible; integrating or editing approaches also require assessment of unintended genomic changes and longer-term risks. Airway samples can establish molecular activity, while lung function, exacerbations, symptoms, and quality of life assess clinical consequences. Sweat chloride, although useful for systemic CFTR treatments, may remain unchanged after a treatment confined to the lungs. Duration of expression and sustained benefit therefore require follow-up beyond an initial biological response. (cff.org)

Research also addresses people with rare or nonsense variants, particularly those whose cells produce little or no protein for modulators to act on. Genetic correction does not remove the need to investigate established infection and organ damage. In the prospective PROMISE microbiology study, published in 2023, sputum from 236 participants showed substantial reductions in several pathogen densities after elexacaftor–tezacaftor–ivacaftor, but most participants remained infected with organisms detected before treatment. Continuing research consequently includes antimicrobial strategies, control of damaging inflammation without weakening host defence, and better assessment and treatment of gastrointestinal, liver, and CF-related diabetes complications. These outcomes require separate measurement rather than being inferred from improved CFTR activity alone. (cff.org)

References

1. Cystic Fibrosis - GeneReviews® - NCBI Bookshelfncbi.nlm.nih.gov
2. Cystic Fibrosis - Causesnhlbi.nih.gov
3. CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG)pmc.ncbi.nlm.nih.gov
4. Types of CFTR Mutationscff.org
5. Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small moleculepmc.ncbi.nlm.nih.gov
6. Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico toolspmc.ncbi.nlm.nih.gov
7. Defective fluid transport by cystic fibrosis airway epithelia.jci.org
8. cAMP stimulates bicarbonate secretion across normal, but not cystic fibrosis airway epithelia.jci.org
9. Defective postsecretory maturation of MUC5B mucin in cystic fibrosis airwayssubmit.jci.org
10. Reduced Airway Surface pH Impairs Bacterial Killing in the Porcine Cystic Fibrosis Lungpmc.ncbi.nlm.nih.gov
11. Development of an airway mucus defect in the cystic fibrosis ratcontent.jci.org
12. Cystic Fibrosis - GeneReviews® - NCBI Bookshelfncbi.nlm.nih.gov
13. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasisjci.org
14. Localization of the cystic fibrosis transmembrane conductance regulator in pancreas.jci.org
15. Localization of the cystic fibrosis transmembrane conductance regulator in pancreas. — PDFjci.org
16. The genesis of cystic fibrosis lung diseasejci.org
17. Contemporary cystic fibrosis incidence rates in Canada and the United Statespmc.ncbi.nlm.nih.gov
18. Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020pmc.ncbi.nlm.nih.gov
19. Cystic fibrosis carrier screening in a North American populationnature.com
20. Cystic Fibrosis - Symptomsnhlbi.nih.gov
21. Cystic Fibrosis - Living Withnhlbi.nih.gov
22. Cystic Fibrosis - GeneReviews®ncbi.nlm.nih.gov
23. Infection Research Initiative White Paper Addendum, August 2020cff.org
24. Research Into Infectionscff.org
25. Pseudomonascff.org
26. Burkholderia Cepacia Complex (B. Cepacia)cff.org
27. Nontuberculous Mycobacteria Clinical Care Guidelinescff.org
28. Allergic Bronchopulmonary Aspergillosis Clinical Care Guidelinescff.org
29. Cystic Fibrosisncbi.nlm.nih.gov
30. Eating Well During and After Pregnancy With Cystic Fibrosis | Cystic Fibrosis Foundationcff.org
31. Complications of cystic fibrosis - Cystic Fibrosis - NCBI Bookshelfncbi.nlm.nih.gov
32. Cystic Fibrosis-Related Diabetes | Cystic Fibrosis Foundationcff.org
33. ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescentspmc.ncbi.nlm.nih.gov
34. Bone Disease in CF Clinical Care Guidelines | Cystic Fibrosis Foundationcff.org
35. Cystic Fibrosis - How Cystic Fibrosis Affects Fertility and Pregnancy | NHLBI, NIHnhlbi.nih.gov
36. Cystic Fibrosis - Diagnosisnhlbi.nih.gov
37. Sweat Testcff.org
38. CF Diagnosis Clinical Care Guidelinescff.org
39. Cystic Fibrosis Foundation Evidence-Based Guideline for the Management of CRMS/CFSPIDpmc.ncbi.nlm.nih.gov
40. Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD)pmc.ncbi.nlm.nih.gov
41. Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Functionpubmed.ncbi.nlm.nih.gov
42. Carrier Screening for Genetic Conditionsacog.org
43. Cystic Fibrosis: Prenatal Screening and Diagnosisacog.org
44. Mucus Thinnerscff.org
45. Cystic Fibrosis - Treatmentnhlbi.nih.gov
46. Antibioticscff.org
47. Evidence-Based Therapeutic Interventionscff.org
48. Enzymescff.org
49. Pancreatic Enzymes Clinical Care Guidelinescff.org
50. Clinical Care Guidelinescff.org
51. Vitaminscff.org
52. Nutritional considerations for a new era: A CF foundation position paperpubmed.ncbi.nlm.nih.gov
53. Cystic Fibrosis-Related Diabetes Clinical Care Guidelinescff.org
54. Use the Right Medicines for Your Digestive Systemcff.org
55. CFTR Modulator Typescff.org
56. CFTR Modulator Therapiescff.org
57. Search Orphan Drug Designations and Approvals: Ivacaftoraccessdata.fda.gov
58. Ivacaftor Summary Reviewaccessdata.fda.gov
59. TRIKAFTA Prescribing Information, August 2023accessdata.fda.gov
60. TRIKAFTA Prescribing Information, 2025accessdata.fda.gov
61. CF Foundation Response to RFI on Improving Access to Gene Therapiescff.org
62. Cystic Fibrosis Researchnhlbi.nih.gov
63. Your CF Care Teamcff.org
64. Screening & Treating Depression & Anxiety Guidelinescff.org
65. Infection Prevention and Control Clinical Care Guidelinescff.org
66. The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal studypubmed.ncbi.nlm.nih.gov
67. Strategies used to access CFTR modulators in countries without reimbursement agreementsspiral.imperial.ac.uk
68. 2025 Patient Registry Highlightscff.org
69. Table 7. Cystic Fibrosis: Recommended Surveillancencbi.nlm.nih.gov
70. 2024 Annual Data Reportcff.org
71. Understanding Changes in Life Expectancycff.org
72. Biography - Dr. Dorothy Hansine Andersennlm.nih.gov
73. Our Historycff.org
74. Discovery of the Cystic Fibrosis Gene | RI History | SickKidssickkids.ca
75. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNApubmed.ncbi.nlm.nih.gov
76. NDA Multi-Disciplinary Review and Evaluation (Kalydeco)fda.gov
77. Search Orphan Drug Designations and Approvals: Trikaftaaccessdata.fda.gov
78. Gene Therapy for Cystic Fibrosiscff.org
79. Genetic Therapies and Treatments for Nonsense and Rare Mutationscff.org
80. Genetic Therapy Delivery for Cystic Fibrosiscff.org
81. Proof of Concept and Early Trial Outcomes for Genetic Therapies Guidance Documentcff.org
82. Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cellsnature.com
83. Inhaled mRNA Therapy for Treatment of Cystic Fibrosis: Interim Results of a Randomized, Double-blind, Placebo-Controlled Phase 1/2 Clinical Studypmc.ncbi.nlm.nih.gov
84. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persistjci.org
85. Research Into Complicationscff.org